Table 3.

Summary of Findings Table.

Statin use and the active tuberculosis infection risk
Patient or population: Overall population or patients with or without the use of statins Settings: Overall population (diabetic or non-diabetic, with or without specific disease), clinical settings Exposure: Statin use
Outcomes	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)
Active tuberculosis infection ICD-9 or ICD-10 diagnosed Follow-up: 1~12 years	RR 0.60 (0.47 to 0.75)	2,133,735 (9 studies)	⊕⊝⊝⊝ lowa, b
*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

^aInconsistency: A considerable heterogeneity was detected which could not be explained by gender difference, diabetic status, study design, or definition of study use.

^bIndirectness: The validity of the definition of statin use and confirmation of active tuberculosis infection outcome were not consistently reported in registries.